about
Positron emission tomography to assess hypoxia and perfusion in lung cancerCombining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenograftsHigh 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidenceCorrelation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT.[18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma.Assessment of intratumor hypoxia by integrated 18F-FDG PET / perfusion CT in a liver tumor model.Hypoxic adaptation engages the CBP/CREST-induced coactivator complex of Creb-HIF-1α in transactivating murine neuroblastic glucose transporter.Relation between primary tumor FDG avidity and site of first distant metastasis in patients with breast cancer.Molecular imaging of hypoxia with radiolabelled agentsCombined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.18[F]FDG-PET/CT is a useful molecular marker in evaluating tumour aggressiveness: a revised understanding of an in-vivo FDG-PET imaging that alludes the alteration of cancer biology.Kinetic modeling in PET imaging of hypoxia.Nitroimidazole derivatives: a patent review of US 2014/0141084 A1.Hypoxia in cervical cancer: from biology to imaging.Impact of Oxygenation Status on 18F-FDG Uptake in Solid Tumors.Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia.Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.Modeling the relationship between fluorodeoxyglucose uptake and tumor radioresistance as a function of the tumor microenvironment.Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.Dose prescription complexity versus tumor control probability in biologically conformal radiotherapy.Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.Utility of early dynamic and delayed post-diuretic 18F-FDG PET/CT SUVmax in predicting tumour grade and T-stage of urinary bladder carcinoma: results from a prospective single centre study.Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer.Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
P2860
Q27026940-6E465F67-3543-4607-B3BD-233B89C4C148Q27329087-B5653867-6A8B-4C12-93F1-D5022CB1FF4CQ33547295-544D5BFA-1C38-494C-89DE-80C9D4705D0EQ33818999-A0BC2F4A-59EA-4F69-BD9B-AC4B0E7AC289Q34301588-3CE51AC2-47E9-45C5-AEDF-8023F3852AF7Q35586691-882793A4-B823-4817-A3E4-A9FB4F0E5BCEQ36298320-E353CDF7-0769-4DE5-8BA1-74FA9691FA09Q36699753-5D1AA43E-392C-4E8B-8F71-8F7FF57AEC31Q37175888-5C3D313D-B0EA-4BD6-B502-0B26AACDF762Q37378239-3D514046-6A85-4A2F-A570-7F18C3AE927BQ37474422-A8F7BFBC-1F35-423D-BF70-36D21A2964A9Q38025952-AFB28084-CA7D-45F7-970D-496297D7AD9CQ38253648-E71FD035-79D2-4A65-B882-11AFFB171481Q38340260-E53D8F5F-F267-40DE-8754-D979A57CA32EQ38643119-DF1AF782-1E0A-496A-A66B-28EA6C06157FQ38802059-72D54625-1392-4403-AC45-6D7B6C9A6DCEQ39485932-EE6F97CA-1807-4EFB-85CC-E5891F9686DEQ39677481-219DC9E2-4DA8-4023-8A14-4D035303008EQ42787448-80708E92-1D11-4716-B2CB-3AE89E91DFD6Q42910924-D2D7E783-145A-421F-A07A-76CD7E1599A9Q42911744-B4E198E3-6EA7-4D96-9C07-3A9AB4A4E9A2Q43297959-F1F876BF-EEC9-4D4C-97E9-3FD23374FF89Q45130105-20DD7F78-2B86-4D74-85AF-380894461578Q51814005-AC03AFE9-4A29-4C58-84BC-AC2327AF84B4Q52897587-DCD359DC-5BE2-45D8-B95F-C9AC76B401D2Q53064658-01FE70BE-CC69-42B1-8AFC-6E4F72495B17Q53193315-80D19113-EE45-4171-88D1-E9500D9AD8EDQ53230858-084775F4-542E-4B0F-A1D3-705ACF833D28
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
FDG uptake, a surrogate of tumour hypoxia?
@ast
FDG uptake, a surrogate of tumour hypoxia?
@en
type
label
FDG uptake, a surrogate of tumour hypoxia?
@ast
FDG uptake, a surrogate of tumour hypoxia?
@en
prefLabel
FDG uptake, a surrogate of tumour hypoxia?
@ast
FDG uptake, a surrogate of tumour hypoxia?
@en
P2860
P921
P1476
FDG uptake, a surrogate of tumour hypoxia?
@en
P2093
Christophe Van de Wiele
Rudi Andre Dierckx
P2860
P2888
P304
P356
10.1007/S00259-008-0758-5
P577
2008-05-29T00:00:00Z
2008-08-01T00:00:00Z